Ovid, UConn Collaborating to Develop shRNA Gene Therapy for Angelman
Researchers at Ovid Therapeutics and the University of Connecticut (UConn) have announced a collaborative effort to expedite the development of a short hairpin RNA (shRNA) therapy for patients with Angelman syndrome. This novel therapeutic approach has potential as a standalone therapy, or in combination with OV101…